HC Wainwright Has Optimistic Outlook of VERV FY2025 Earnings

Verve Therapeutics, Inc. (NASDAQ:VERV) – Equities researchers at HC Wainwright raised their FY2025 earnings per share estimates for Verve Therapeutics in a report released on Monday, May 19th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($2.16) for the year, up from their prior estimate of ($2.38). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Verve Therapeutics’ current full-year earnings is ($2.49) per share. HC Wainwright also issued estimates for Verve Therapeutics’ Q1 2026 earnings at ($0.61) EPS, Q2 2026 earnings at ($0.66) EPS, Q3 2026 earnings at ($0.68) EPS and Q4 2026 earnings at ($0.70) EPS.

Several other brokerages also recently issued reports on VERV. Canaccord Genuity Group raised their price objective on shares of Verve Therapeutics from $32.00 to $39.00 and gave the stock a “buy” rating in a research report on Tuesday, April 15th. Cantor Fitzgerald upgraded Verve Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Tuesday, April 15th. Royal Bank of Canada cut their price target on Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a research note on Tuesday, March 4th. Guggenheim upped their price objective on shares of Verve Therapeutics from $18.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, April 15th. Finally, William Blair reaffirmed an “outperform” rating on shares of Verve Therapeutics in a report on Friday, February 21st. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $25.75.

Verve Therapeutics Trading Up 5.5%

Shares of NASDAQ VERV opened at $4.61 on Wednesday. The stock has a market cap of $410.95 million, a P/E ratio of -1.87 and a beta of 1.82. Verve Therapeutics has a twelve month low of $2.86 and a twelve month high of $9.31. The stock has a 50 day moving average of $4.71 and a two-hundred day moving average of $5.84.

Verve Therapeutics (NASDAQ:VERV) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.36. The company had revenue of $32.98 million for the quarter, compared to analyst estimates of $7.13 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%.

Hedge Funds Weigh In On Verve Therapeutics

A number of large investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC increased its stake in Verve Therapeutics by 465.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 42,781 shares of the company’s stock worth $241,000 after buying an additional 35,214 shares during the period. Impact Partnership Wealth LLC bought a new stake in shares of Verve Therapeutics during the 4th quarter worth $70,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Verve Therapeutics by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,952 shares of the company’s stock worth $101,000 after acquiring an additional 1,676 shares during the last quarter. Rhumbline Advisers raised its position in shares of Verve Therapeutics by 1.9% during the fourth quarter. Rhumbline Advisers now owns 111,203 shares of the company’s stock worth $627,000 after purchasing an additional 2,093 shares during the period. Finally, IFP Advisors Inc boosted its position in shares of Verve Therapeutics by 823,700.0% in the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock valued at $47,000 after purchasing an additional 8,237 shares during the period. Hedge funds and other institutional investors own 97.11% of the company’s stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.